Pfizer drug linked to higher heart failure rate

Small study shows cancer patients taking Pfizer's Sutent suffered 15% rate of heart failure, higher than in clinical trials.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

Heart, brain health linked
CNN's Dr. Sanjay Gupta reports on new findings that emphasizes the connection between heart health and brain health.

NEW YORK (CNNMoney.com) -- A new study released at a conference on Tuesday shows that Pfizer's cancer drug Sutent may be linked to more instances of heart failure than previously thought.

Some 15% of patients suffered heart failure when taking Sutent, according to results from a small study, announced at the Genitourinary Cancers Symposium in San Francisco.

The study found that seven out of 48 patients receiving Sutent experienced heart failure. This is a higher rate than previously recognized, according to the American Society of Clinical Oncology (ASCO), co-sponsor of the symposium.

Prior results from clinical trials showed an 8% heart failure rate, according to ASCO. The new study, lead by researcher Dr. Melinda Telli of the Stanford University School of Medicine, was not a clinical trial, and tracked patients from 2004 to 2007.

Dr. Telli acknowledged that the study was "limited by the numbers," but said "it's possible that the true incidence of heart failure could be even higher." She said that doctors should conduct routine monitoring of Sutent patients to detect problems with heart function.

Barbara Ryan, analyst for Deutsche Bank North America, said that the issue "probably warrants further investigation," but it's difficult to draw any conclusions, "given the small size of the study."

Sutent is an FDA-approved treatment for cancer of the kidney and digestive system. Sales for the drug totaled $581 million in 2007, up 166% from $219 million the prior year.

Pfizer (PFE, Fortune 500) did not fund this study.

Pfizer spokeswoman Vanessa Aristide said that Pfizer has not had an opportunity to review the data. But she stressed that cardiovascular events are acknowledged on Sutent safety labels, along with recommendations for monitoring patients with cardiac risk factors.

She also said the risk-benefit profile of Sutent is "well established," and the drug has been studied in 33,000 people. To top of page

Photo Galleries
10 of the most luxurious airline amenity kits When it comes to in-flight pampering, the amenity kits offered by these 10 airlines are the ultimate in luxury More
7 startups that want to improve your mental health From a text therapy platform to apps that push you reminders to breathe, these self-care startups offer help on a daily basis or in times of need. More
5 radical technologies that will change how you get to work From Uber's flying cars to the Hyperloop, these are some of the neatest transportation concepts in the works today. More
Sponsors

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.